
[February, 2008 – December, 2010]
Randomized (n=200)
Allocated to IA-HA (n=100)
(High molecular weight 2,700 kDa HA, Suvenyl®)
Allocated to NSAID (n=100)
(loxoprofen sodium, Loxonin®)
Excluded (n=1)
◆ Withdrew consent before initial administration (1)
Excluded (n=7)
◆ Duplicated recruiting (1)
◆ Withdrew consent before initial administration (6)
FAS data set
(n=192)
Eligible to efficacy
(n=99)
Eligible to efficacy
(n=93)
Excluded (n=1)
◆Lost to follow up (n=1)
Excluded (n=7)
◆Lost to follow up (n=7)
Primary endpoint
To analysis for JKOM score
(n=184)
Eligible to efficacy
(n=98)
Eligible to efficacy
(n=86)
Secondary endpoint
Excluded (n=1)
◆ No VAS score at initial assessment
To analysis for VAS score
(n=182)
Excluded (n=1)
◆ No VAS score at final assessment
Eligible to efficacy
(n=97)
Eligible to efficacy
(n=85)